What is the official website of Novartis Finland ?

The official website of Novartis Finland is https://www.novartis.fi/.

What is Novartis Finland's cybersecurity risk score?

Novartis Finland has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Finland experienced?

According to Rankiteo, Novartis Finland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Finland been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Finland has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Finland have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Finland is not certified under SOC 2 Type 1.

Does Novartis Finland have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Finland does not hold a SOC 2 Type 2 certification.

Does Novartis Finland comply with GDPR ?

According to Rankiteo, Novartis Finland is not listed as GDPR compliant.

Does Novartis Finland have PCI DSS certification ?

According to Rankiteo, Novartis Finland does not currently maintain PCI DSS compliance.

Does Novartis Finland comply with HIPAA ?

According to Rankiteo, Novartis Finland is not compliant with HIPAA regulations.

Does Novartis Finland have ISO 27001 certification ?

According to Rankiteo,Novartis Finland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Finland operate in ?

Novartis Finland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Finland have ?

Novartis Finland employs approximately 46 people worldwide.

Does Novartis Finland own any subsidiaries ?

Novartis Finland presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Finland have ?

Novartis Finland's official LinkedIn profile has approximately 3,076 followers.

What is the NAICS classification code for Novartis Finland ?

Novartis Finland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Finland have a Crunchbase profile ?

No, Novartis Finland does not have a profile on Crunchbase.

Does Novartis Finland have a LinkedIn profile ?

Yes, Novartis Finland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-finland.

How many cybersecurity incidents has Novartis Finland experienced ?

As of October 7, 2026, Rankiteo reports that Novartis Finland has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Finland have ?

Novartis Finland has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Finland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Finland

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Novartis Finland Vendor Cyber Rating & Cyber Score

novartis.fi

Add Your Compliance Badge

Tehtävämme on pidentää ja parantaa ihmisten elämää. Luomme innovatiivisen tutkimuksen ja digitaalisten teknologioiden avulla uudenlaisia hoitoja vastaamaan merkittäviin lääketieteellisiin tarpeisiin. Toimimme osana terveysalan ekosysteemiä ja olemme avoimia yhteistyölle. Pyrimme kaikessa toiminnassamme korkeaan eettiseen tasoon. LinkedInissa kerromme siitä, mitä teemme ja millaista on työskennellä Novartiksella. Tämän LinkedIn-sivun yhteisösäännöt ja tietosuojailmoitus: www.novartis.fi/linkedin #reimaginingmedicine #novartislife

Novartis Finland

Novartis Finland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Finland

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Finland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Finland in 2026.

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Finland in 2026.

Incident History - Novartis Finland (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Finland Subsidiaries

Novartis Finland

Pharmaceutical Manufacturing

Website: https://www.novartis.fi/

Company Size: 46

NovartisPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis ColombiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Loading…

Novartis Finland Similar Companies

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

Novartis Finland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-97626

SUMMARY

Requesting a user or organization profile page (`GET /{username}`) with an `Accept: application/rss+xml` or `Accept: application/atom+xml` header returned the owner's activity feed without the visibility check that the profile page and the `.rss` and `.atom` routes apply. Anonymous users, restricted users and non-members could confirm the existence of limited or private users and private organizations and read their profile details and public activity, also when `[other] ENABLE_FEED` was disabled. Activity in private repositories was not included.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-97208

SUMMARY

The Gitea API endpoint for creating push mirrors (`POST /api/v1/repos/{owner}/{repo}/push_mirrors`) checked only whether mirroring was enabled and not the `[mirror] DISABLE_NEW_PUSH` setting that the web interface enforces. A repository administrator could therefore create new push mirrors on instances where the site administrator had disabled them. A push mirror pushes all refs of the repository to a remote chosen by the caller, on each commit or on a schedule.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-96594

SUMMARY

The Gitea API endpoint `GET /api/v1/repos/{owner}/{repo}/media/{filepath}` wrote files of up to 1 KiB that are stored directly in Git, not in LFS, to the response without the content type and disposition headers Gitea uses for user content. An HTML file committed to a repository was therefore rendered by the browser on the Gitea origin. A user who can push to a repository could run JavaScript in the session of a victim who opens the media URL and act with the victim's permissions.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-89182

SUMMARY

With `[repository] FORCE_PRIVATE = true`, Gitea creates new repositories as private, but the post-receive hook still applied the `repo.private=false` push option to an empty repository created by push. Any user who can create repositories could make their new repository public in violation of the instance policy. The default configuration is not affected.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-86684

SUMMARY

The Gitea push mirror API checked whether the repository owner, instead of the requesting user, may use local file system paths. On instances with `[security] IMPORT_LOCAL_PATHS = true`, a repository administrator who is not allowed to import local paths could add a push mirror to a local path on the server when the repository owner has that permission. Gitea then pushed the repository's refs into an existing Git repository at that path with the permissions of the Gitea process.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Finland Vendor Cyber Rating & Cyber Score

Novartis Finland A.I CyberSecurity Scoring

Novartis Finland CyberSecurity News & History

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Finland (X = Date, Y = Severity)

Novartis Finland Subsidiaries

Novartis Finland

Novartis Finland Similar Companies

AUROBINDO PHARMA LTD

Johnson & Johnson Innovative Medicine

Merck

SUN PHARMA

Astellas Pharma

Catalent

Glenmark Pharmaceuticals

Cipla

Lonza

Novartis Finland CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Finland CyberSecurity News & History

Novartis Finland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Finland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Finland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Finland (X = Date, Y = Severity)

Novartis Finland Subsidiaries

Novartis Finland

Novartis Finland Similar Companies

AUROBINDO PHARMA LTD

Johnson & Johnson Innovative Medicine

Merck

SUN PHARMA

Astellas Pharma

Catalent

Glenmark Pharmaceuticals

Cipla

Lonza

Novartis Finland CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo